Introduction
============

Chronic myeloid leukemia (CML) is a disease associated with a characteristic chromosomal translocation between chromosomes 9 and 22, the Philadelphia chromosome (Ph^+)^, resulting in an increased and unregulated growth of myeloid cells^([@r01])^.

In the last decade, there has been a revolution in CML treatment with the introduction of tyrosine kinase inhibitors (TKIs)^([@r02])^. Imatinib mesylate (IM) has become the frontline therapy for CML^([@r03],[@r04])^. Treatment efficacy is determined by the drug itself, adhesion to therapy and intrinsic characteristics of patients, which directly impact on therapeutic response^([@r05],[@r06])^. Periodic assessment of response is important to assure an effective treatment regimen. This study evaluated the therapeutic efficacy of IM treatment in patients with CML and identified its determinants.

Methods
=======

This retrospective study was based on information obtained from patients\' records in the Hematology Service of *Hospital Universitário Walter Cantídio*of *Universidade Federal do Ceará*(HUWC / UFC), in northeast Brazil. The study was approved by that institution\'s Ethics Research Committee.

Population and Sample
---------------------

All patients diagnosed with CML that took IM for a minimum of 12 months in the period from January 2001 to January 2011 were included in the study. From a population of 160 patients, 100 were eligible for analysis. In the assessment of factors related to treatment response, two patients were excluded because they were referred for bone marrow transplantation (BMT) before response evaluation. A special form was used to collect sociodemographic characteristics and data related to diagnosis and therapeutic response based on the LeukemiaNet criteria^([@r07])^ (hematologic, cytogenetic and molecular), as well as time to response and adherence to treatment.

Prognostic factors
------------------

The risk factors at diagnosis were based on Brazilian Health authorities recommendations^([@r08])^ as adopted by the Hematology Service of the hospital. The Sokal score^([@r09])^ was used to stratify patients in low risk, intermediate-risk and high-risk groups based on the following criteria for poor prognosis: 60 years of age, splenomegaly 10 cm below the costal margin, platelet count of 700 x 10^9^/L, 3% blasts in the bone marrow or peripheral blood and 7% of blood basophils or 3%in bone marrow. The low risk group was characterized by 0 and 1 of these criteria, the intermediate risk by 2 and high risk by three criteria.

Adhesion
--------

The medication possession ratio (MPR), often adopted to evaluate compliance was used, taking into consideration the days without medication in intervals between drug dispensation^([@r10])^.

Reticulin condensation
----------------------

Reticulin condensation, evaluated by bone marrow biopsy at diagnosis, was categorized in two groups: positive for any degree of fibrosis or negative for no fibrosis.

Response analysis
-----------------

The criteria for response analysis were based on the Leukemia Net guidelines^([@r07])^. On several occasions protocol follow up examinations were missing due to financial difficulties and limited availability in Brazilian National Healthcare System (SUS) institutions.

Outcome
-------

Patients were categorized in two groups regarding the outcome: positive or negative. The group with positive outcomes obtained therapeutic success. Negative outcomes were characterized if either failure, loss of response, death, suspension because of myelotoxicity or gastrointestinal intolerance, noncompliance or adherence \< 90% was observed^([@r11])^.

Statistical analyses
--------------------

Statistical analyses were performed using the R software (version 2.15). A p-value \< 0.05 was considered significant. Categorical data were analyzed using the Fisher\'s exact test.

Results
=======

The population consisted of 100 patients who were mostly male (51%) with, in general, ages ranging from 21 to 40 years (42%) and a median of 41.5 years, from the countryside (59%), in the chronic phase (95%), with high-risk prognostic factors (40%),presenting with splenomegaly (76%), Hemoglobin \< 11.5 g/dL(72%), asthenia (44%), pallor (38%) and hepatomegaly (37%), cytogenetics at diagnosis with 100% Ph^+^ (81%) and that hadmade leuko reduction only with hydroxyurea (88%) ([Table 1](#t01){ref-type="table"}).

###### 

Patient characteristics

  **Variable**                    \%                       
  ------------------------------- ------------------------ ----
  **Gender**                                               
                                  Male                     51
                                  Female                   49
  **Age (years) (mean = 41.5)**                            
                                  ≤ 20                     06
                                  21-40                    42
                                  41-60                    35
                                  \> 60                    17
  **Origin**                                               
                                  State capital            41
                                  Countryside              59
  **Disease phase**                                        
                                  Chronic                  95
                                  Accelerated              04
                                  Blastic                  01
  **Prognostic factors**                                   
                                  Low risk                 31
                                  Intermediate risk        26
                                  High risk                40
                                  Undetermined             03
  **Presentation at diagnosis**                            
  Splenomegaly                    76                       
  Hemoglobin \< 11.5 g/dL         72                       
  Hepatomegaly                    37                       
  **Cytogenetics**                                         
                                  100% Ph+                 81
                                  \< 100% Ph+              08
                                  0%                       04
                                  Inconclusive             02
                                  Not done                 05
  **Leukoreduction**                                       
                                  Hydroxyurea              88
                                  Busulfan + Hydroxyurea   07
                                  Others                   05

Ph^+^: Philadelphia chromosome

[Table 2](#t02){ref-type="table"} shows that the prognosis of high risk was not associated with complete hematologic response (CHR) or complete cytogenetic response (CCR), but correlated to complete molecular response (CMR) or major molecular response (MMR). Reticulin condensation was associated with CHR and CCR. However there was no associated with CMR or MMR. Furthermore, there was no association between metaphases with 100% Ph^+^ and diagnosis or response achieved. The other cytogenetic changes at diagnosis correlated only with CHR. The time between diagnosis and the beginning of IM treatment of less than 12 months was only correlated to CCR.

###### 

Factors associated with therapeutic response

                                      **CHR**                    **CCR**                                                                      
  ----------------------------------- ------------- ------------ ---------------------- ------------- --- ------------- ------------ -------- -------------
  High-risk prognosis                 40.7          40.0         1.03                   1.0000            38.9          44.2         0.80     0.6547
  Reticulin condensation              61.3          0.0          \-                     0.0670            34.6          67.9         0.25     0.0283
  Metaphase with 100% Ph+             86.2          100.0        \-                     1.0000            77.1          92.7         0.27     0.0991
  Additional cytogenetic alteration   14.1          60.0         0.11                   0.0311            09.1          17.1         0.49     0.4963
  ΔT DX-IM \< 12 months               43.0          16.7         3.77                   0.3960            57.9          31.8         2.95     0.0255
  Beginning of treatment in CP        57.0          16.7         6.63                   0.0892            78.9          45.5         4.50     0.0029
  Adhesion ≥ 90%                      53.8          50.0         1.16                   1.0000            73.7          50.0         2.80     0.0409
  Positive outcome                    34.8          0.0          \-                     0.1731            78.9          04.5         78.75    \< 0.0001
                                      **CMR/MMR**                **Positive Outcome**                                                         
                                      **Yes (%)**   **No (%)**   **OR**                 **p-value**       **Yes (%)**   **No (%)**   **OR**   **p-value**
  High-risk prognosis                 30.0          58.8         0.30                   0.0257            36.7          41.5         0.81     0.8221
  Reticulin condensation              36.4          61.9         0.35                   0.1308            26.3          71.7         0.14     0.0010
  Metaphase with 100% Ph+             79.3          87.9         0.53                   0.4932            78.6          90.6         0.38     0.1755
  Additional cytogenetic alteration   6.9           16.7         0.37                   0.4238            11.1          19.0         0.53     0.5387
  ΔT DX-IM\* \< 12 months             64.5          41.2         2.60                   0.0828            62.5          30.3         3.83     0.0040
  Beginning of treatment in CP        77.4          50.0         3.43                   0.0386            81.2          42.4         5.88     0.0004
  Adhesion ≥ 90%                      80.6          50.0         4.17                   0.0185            81.2          40.9         6.26     0.0002
  Positive outcome                    83.9          9.1          52.00                  \< 0.0001         \-            \-           \-       \-
                                                                                                                                              
  **CCR in less than 12 months**                                                                                                              
  **Yes (%)**                         **No (%)**    **OR**       **p-value**                                                                  
  Adhesion ≥ 90%                      90.5          50.8         8.44                   0.0232                                                

CHR: Complete hematologic response; CCR: Complete cytogenetic response; CMR: Complete molecular response; MMR: major molecular response;

Ph^+^: Philadelphia chromosome positive; IM: imatinib; ΔT DX-IM: Time between diagnosis and starting imatinib treatment; CP: chronic phase

Adherence \> 90% was correlated with CCR and CMR or MMR. The positive outcome was strongly associated with CCR and CMR or MMR.

Two patients were excluded who did not complete the monitoring of therapeutic response, although they had been treated with IM for 12 months before being referred for BMT.

In this study, 53% of patients had greater than 90% adherence. Among the patients with CCR (38%), twenty-seven (71%) had adherence ≥ 90% as shown in [Table 2](#t02){ref-type="table"}. The high adherence was correlated to achieving CCR within 12 months. Of the 23 patients that achieved CCR within 12 months, nineteen (82.6%) had ≥ 90% adherence. Some patients did not perform the cytogenetic (20%) and molecular exams (35%) to monitor therapeutic response.

[Table 3](#t03){ref-type="table"} shows that 20% of patients had good response, 26% failure, 19% no response, 13% suspended treatment due to myelotoxicity/intolerance, the response was lost in 4%, 4% abandoned treatment and 2% were referred for BMT.

###### 

Treatment outcome

  **Treatment outcome with imatinib**   **Condition in January 2011**                           
  ------------------------------------- ------------------------------- ----------------------- -----
  Optimal                               20                                                      
  Sub-optimal                           12                              Imatinib                35
  Failure                               26                              Dasatinib               18
  No response                           19                              Nilotinib               9
  Suspended                             13                              Hydroxyurea             4
  Loss of best response possible        4                               Subtotal                66
  Abandoned treatment                   4                               Death                   21
  Bone marrow transplantation           2                               Loss to follow-up       11
                                                                        Watch and see           1
                                                                        Second-generation TKI   1
  Total                                 100                             Total                   100

TKI: tyrosine kinase inhibitors

Suspension was due to myelotoxicity/intolerance

At the end of the study, 65% of the population was under treatment using medications, 22% died with one suicide and 2% had been referred for BMT ([Table 3](#t03){ref-type="table"}).

Of the patients on treatment, 34% were treated with IM and 27% with 2nd generation TKI as follows: 18% with dasatinib, 9% with nilotinib and 4% with hydroxyurea.

There was a correlation between a positive outcome and early use of IM within 12 months of diagnosis (62.5%) and the beginning of treatment in chronic phase (81.2%). [Figure 1](#f01){ref-type="fig"} shows that the proportion of patients with good therapeutic response over time is greater in the group of patients that started treatment with TKIs within 12 months after diagnosis (p-value = 0.0001: log-rank test - Kaplan Meier curve).

![Kaplan-Meier curve presenting freedom from therapeutic failure with regard to starting time of TKIs](rbhh-35-06-0389-g01){#f01}

Of the 100 patients, 12% had additional cytogenetic changes at diagnosis that were possibly related to an unfavorable outcome ([Table 4](#t04){ref-type="table"}). One patient presented the change i(17) at diagnosis and evolved with the T315I mutation.

###### 

Cytogenetic alterations at diagnosis and outcome

  **Cytogenetic changes at diagnosis**   **n**   **Outcome**                      **Occurrence**
  -------------------------------------- ------- -------------------------------- -------------------------------
  t(9;14;22)                             1       No response                      Clonal evolution
  t(9;22;17)                             1       No response                      L364I mutation
  t(9;21;22)                             2       Failure                          Clonal evolution
  t(2;9;19;20;22)                        1       CCR                              Slow and progressive response
  double Ph+                             1       No response                      Cytopenias
                                         1       Suspended due to myelotoxicity   Blastic crisis
  i(17)                                  1       Failure                          T315I mutation
  46, XX,+22                             1       Failure                          Clonal evolution
  inv(9)                                 1       Suspended due to myelotoxicity   Clonal evolution
  del(9)(q34)                            1       PCR                              Cytopenias
  loss chromosomal casual                1       Suspended due to myelotoxicity   Blastic crisis
  Total                                  12                                       

CCR: Complete cytogenetic response; PCR: Partial cytogenetic response

Discussion
==========

Most cases of CML occur in adults between 40 and 60 years old, with an incidence of about 1 case in 100,000 individuals^([@r12])^. In the present study, the most prevalent age group was between 21 and 40 years. Splenomegaly, hemoglobin \< 11.5 g/dL and hepatomegaly were the main features at presentation. Most patients presented disease in the chronic phase with high-risk prognostic factors at diagnosis ([Table 1](#t01){ref-type="table"}).

The chronic phase, adhesion ≥ 90%, time between diagnosis and initiation of IM treatment of less than 12 months and absence of reticulin condensation were strongly associated with CCR and a favorable outcome in this series ([Table 2](#t02){ref-type="table"}). Patients who started treatment within 12 months after diagnosis, initiated treatment in the chronic phase and had adhesion ≥ 90% presented lower failure and loss of response rates.

In the last decade, several studies demonstrated the efficacy and determinants of therapeutic response to IM. The ability to calculate high risk rates for individual patients will make it possible to examine the patient groups for status and initial risk and to stratify the patients according to the prognosis classification. The effects of treatment on survival can then be evaluated with greater precision, both in retrospective reviews of completed studies and in potential therapeutic trials^([@r09])^.

The Sokal score was not used in this series but one based on Brazilian health ministry determinations^([@r08])^; there was no association between high risk prognosis and CHR or CCR ([Table 2](#t02){ref-type="table"}) or negative outcomes ([Table 3](#t03){ref-type="table"}.) Probably these results are related to the risk stratification used in Brazilian patients.

Treatment response to IM varies among patients. The principle for this variation is unknown and lack of adherence is a relevant problem^([@r13])^. Compliance has been demonstrated as one of the most important factors. Non-adherence to long-term oral therapies leads to a decrease in plasma levels of the drug. There is a correlation between low plasma levels of IM and failure to achieve a cytogenetic response^([@r14])^. A sub analysis of the International Randomized Study of Interferon and STI571 study (IRIS) showed that patients whose plasma concentrations of IM were higher than 1000 ng/mL showed higher rates of CCR^([@r15])^. A similar result was demonstrated in the present study with the association between adhesion ≥ 90% and CCR and a shorter time to response ([Tables 2](#t02){ref-type="table"}). Furthermore, adherence was strongly associated with positive outcomes and related to therapeutic efficacy.

Previous studies have shown that better IM compliance is also associated with a substantially lower medical care need and lower costs in health care compared to poor compliance^([@r16],[@r17])^.

The database of the Brazilian Heath Ministry, DATASUS, showed that from 2001 to 2007, there was an increase of 40% of high-complexity procedures in oncology representing a 63% increase in expenses for outpatient chemotherapy. In the specific case of CML, the increase in costs was 307%, mainly due to the introduction of IM in the Brazilian National Health System in 2001^([@r18])^. At this time, according to Brazilian guidelines, IM was prescribed as first-line treatment for patients in accelerated phase (AP) or blast crisis (BC) and as a second-line for patients in chronic phase and intolerant to interferon. Only in 2008, IM was adopted as first-line treatment for CML in chronic phase, with this greatly impacting the prescription of IM in our clinic. It is possible that two-week prescriptions had a negative impact on adherence in our institution.

Any degree of myelofibrosis is historically associated with poor prognosis of CML. There is a change in the distribution of elements in the extracellular matrix of the bone marrow and it has been suggested that the leukemia cells are protected or \"hidden\" by these elements. Some studies have shown that IM acts on bone marrow stroma^([@r19],[@r20])^. The drug acts by blocking binding to the adenosine triphosphate (ATP), the binding site of the tyrosine kinase domain in the breakpoint cluster region/Abelson (BCR/ABL) protein and has also an independent anti-fibrotic effect in patients with CML. However, an increase of fibrosis could prevent the drug to act by not allowing apoptosis of Ph^+^ cells^([@r20])^. A recent study demonstrated a significant correlation between cytogenetic response and the degree of reticulin thickening. In our study, reticulin condensation was negatively associated with CCR ([Table 2](#t02){ref-type="table"}) and a positive outcome ([Table 2](#t02){ref-type="table"}) showing that myelofibrosis works as an unfavorable prognostic factor to response and prognosis^([@r21])^.

The use of IM in more advanced phases of disease is associated with higher frequency of drug resistance. In addition, some negative outcomes were related to the presence of specific mutations ([Table 4](#t04){ref-type="table"}).

Most cases of failure to treatment with IM unrelated to excessive toxicity are the result of one or more resistance mechanisms^([@r22])^. The variability in the pharmacokinetics of IM has also been mentioned as a possible mechanism to explain suboptimal response or treatment failure. Patients with lower plasma levels are less likely to respond to therapy^([@r14],[@r15])^. Resistance to IM can be multifactorial as rapid detection of primary resistance or intolerance provides rescue response and increased survival in patients with CML^([@r23])^.

The most common cause of secondary resistance is a loss of inhibition of BCR-ABL resulting from mutations of ABL present in 50-90% of cases^([@r24],[@r25])^. Mutations are more frequent in secondary resistance than the primary (57% vs. 30%) and also in advanced stages (80% in the blast phase vs. 14% in the chronic phase)^([@r25])^. Other known mechanisms of resistance include secondary overproduction of BCR-ABL due to genetic amplification^([@r24])^, the appearance of additional Ph^+^ chromosomes or other chromosomal abnormalities (clonal evolution)^([@r26])^.

In our series, among patients with mutations at diagnosis, only two had a favorable outcome (16.6%) with an optimal response. Patients who showed intolerance or resistance to IM received second-generation TKI such as dasatinib (18%) and nilotinib (9%). Many of them presented a successful outcome. However, some patients had no access to second-generation TKIs due to financial difficulties and limited availability in Brazilian healthcare institutions.

Conclusions
===========

Several factors were correlated to the success of IM therapy in our population, especially starting treatment in the chronic phase and less than 12 months after diagnosis, adhesion ≥ 90% and absence of reticulin condensation. All these factors showed a strong association with CCR, but it is evident that the number of adverse outcomes was greater than the positive outcomes. This fact possibly occurred due to the start of treatment with IM in more advanced stages of the disease, poor access to medication and the monitoring of therapeutic responses as consequences of the financial difficulties faced by Brazilian institutions.

The monitoring of reticulin condensation seems to contribute to future therapeutic decisions considering the lower performance of IM in cases with a high-degree fibrosis.

The score adopted in our institution showed no correlation with the extent of CCR.

Significant changes to monitoring of patients with CML are necessary, as are the development of strategies to manage patients with failure not only in respect to the medication supply, but also to monitor therapeutic responses. In our series few patients performed cytogenetic and molecular analyses as recommended.

The importance of a multidisciplinary team to provide patients with the full treatment was also evident. Nevertheless, even with a large percentage of negative outcomes,the improvement in the quality of life of patients with CML is remarkable.
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